In-House Clinical Research Associate (CRA)

About the Role

Join us in shaping the future of pain management by ensuring top quality standards across our clinical trials. You will play an integral role in actively developing our Clinical Quality Assurance (CQA) system, promptly detecting risks, and guaranteeing compliance with regulatory requirements. Collaborating closely with internal teams and external partners, you will drive continuous improvements to uphold consistent quality standards. If you are ready to take responsibility and truly make an impact, we want to hear from you!

Key Responsibilities

• Contribute to the design, maintenance, and enhancement of our Clinical Quality Assurance system.
• Focus on identifying, documenting, assessing, and following up on protocol deviations and non-compliance issues at study centers.
• Detect emerging trends early to implement preventive measures.
• Coordinate with external service providers such as monitoring CROs to prevent and resolve non-compliance through development of Corrective and Preventive Actions (CAPA).
• Act as a strategic advisor to the Clinical Operations team on all center-related Good Clinical Practice (GCP) topics.

Candidate Profile

• Holds a degree in Medicine, Life Sciences, Pharmacy, Biotechnology, or a related field.
• Possesses at least one year of prior experience in clinical research and quality assurance, ideally with prior CRA experience.
• Demonstrates solid understanding of ICH GCP E6 guidelines and related regulations.
• Experience in designing and improving corporate processes.
• Works independently, with a results-oriented and structured approach.
• Fluent in both German and English at a minimum C1 proficiency level.

About Us

Vertanical is a globally recognized biopharmaceutical company specializing in innovative drugs for chronic pain management. We are committed to a vision of a world free from chronic pain. Our pioneering cannabinoid-based medication VER-01 (marketed as Exilby in Germany and Austria since June 2026) represents the culmination of over eight years of dedicated research and development. U.S. market approval is anticipated in 2029, with the goal to establish Exilby as the leading therapy for chronic pain by 2030, setting new benchmarks in pain care.

Our Commitment to You

We provide a challenging and diverse position with exciting responsibilities and broad scope for creativity. Our innovative environment supports your professional growth with swift decision-making processes, full ownership from day one, and the freedom to explore new approaches. You will benefit from personalized learning opportunities and contribute meaningfully to improving millions of lives.

Additional Information

Note: For readability, the masculine form is used in this announcement but expressly refers to all genders (male/female/diverse).